BioHarvest Provides Unmatched Consistency & Variety in Cannabis


2021-09-14 04:00:10 CFN Media Group


  The cannabis industry is quickly evolving from dried cannabis to beverages and other product formats. At the same time, the pharmaceutical industry is increasingly embracing cannabinoids for their potential therapeutic benefits. The challenge is converting raw plant material into a consistent format with the right mix of cannabinoids. Let’s look at the importance of consistency in the cannabis industry, why some cannabinoids are so challenging to produce, and how BioHarvest Sciences Inc. (CSE: BHSC) is overcoming these hurdles with its innovative biofarming platform. The cannabis and hemp industries typically use inexact science to produce cannabinoids. While some variability is okay for recreational markets, food- and medical-grade markets must meet higher regulatory standards. For instance, the large number of recalls affecting the recreational market would never be acceptable for pharmaceutical companies.  Cannabis and hemp cultivators typically use specific strains to achieve the right mix of cannabinoids. Aside from genetic drift over time, cannabinoid concentrations depend on plant specific light, temperature, humidity, and nutrients. The combination of genetic and atmospheric variability makes it hard to produce plants with a consistent profile. The next stage of the process is extraction, which introduces more variables and uncertainty. For example, extractors must purchase raw materials free from heavy metals, pesticides, and other contaminants resulting from cultivation processes. Distillation processes also rely on exact temperature, pressure, and other factors to ensure purity. Cannabis plants are inherently high in THC and CBD, but there are also hundreds of other potentially valuable cannabinoids. For example, CBN, CBG, CBC, and THCV are rare cannabinoids that makeup just 0.01% to 10% of the total plant mass. There’s a large amount of plant mass required to produce a relatively small amount of rare cannabinoids. Rare Cannabinoids – Source: Rare Cannabinoid Company These dynamics are particularly problematic for pharmaceutical companies seeking a specific rare cannabinoid for mass production. Synthetic cannabinoids provide a compelling alternative, but these molecules lack the entourage effect that involves terpenes. And emerging research suggests that terpenes could positively impact certain clinical outcomes. BioHarvest Sciences Inc. (CSE: BHSC) starts with a single mother plant with the desired active phytocannabinoids. Then, the scientists take small parts from the plant and grow the cells on a Petri dish on a solid medium that contains nutrients for its growth. These cells become a microcosm of nature containing the components from the mother plant in their original structure.  These cells now constitute a “cell bank” for perpetual and homogeneous production. They can then be grown in liquid mediums in large bioreactors in 3-4 week cycles, which translates to 13-17 cycles each year. Furthermore, the biofarming process occurs in aseptic conditions in total compliance with ISO and GMP requirements, eliminating the potential for contamination.  After the cells reach adequate biomass, they are dried into a final powder form. The powder contains the desired active phytocannabinoids and other plant characteristics that create an entourage effect. These powders are ideal for use in cannabinoid-based foods, beverages, or pharmaceuticals that require perfect fingerprint consistency. Benefits of Biofarming – Source: BioHarvest In addition to unmatched consistency and rapid production cycles, the biofarming process uses far less water, energy, and other resources than conventional cultivation. These attributes are essential given the water shortages in the Western United States and the tremendous amount of energy required to grow cannabis indoors. BioHarvest Sciences Inc. (CSE: BHSC) has built an impressive biofarming platform capable of scaling up the production of valuable cannabinoids. The company has already leveraged the platform to extract valuable phytochemicals out of red grapes at scale. Its VINIA® product line is a proprietary red grape product containing the entire matrix of polyphenols in red grapes. Each 400mg serving contains the same amount of Piceid Resveratrol as a whole bottle of wine. The same platform could revolutionize the cannabis industry as the company also sets its sights on unlocking the benefits of olives and pomegranates through other products. For more information, visit the company’s website or download their investor presentation. Disclaimer The above article is sponsored content. and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
大麻产业正在迅速从干大麻发展到饮料和其他产品形式。与此同时,制药行业越来越多地接受大麻素,因为它们有潜在的治疗好处。目前的挑战是用大麻素的正确组合将原材料转化为一致的格式。 让我们看看一致性在大麻行业的重要性,为什么一些大麻素生产如此具有挑战性,以及生物收获科学公司(CSE:BHSC)如何通过其创新的生物武器平台克服这些障碍。 大麻和大麻工业通常使用不精确的科学来生产大麻素。虽然娱乐市场有一些可变性是可以的,但食品和医疗市场必须符合更高的监管标准。例如,影响娱乐市场的大量召回对制药公司来说是永远不能接受的。 大麻和大麻种植者通常使用特定的菌株来实现大麻素的正确混合。除了基因随时间漂移,大麻素的浓度取决于植物特定的光照、温度、湿度和营养物质。遗传和大气变异性的结合使得很难生产出具有一致剖面的植物。 该过程的下一阶段是提取,它引入了更多的变量和不确定性。例如,提取者必须购买不含重金属、杀虫剂和栽培过程中产生的其他污染物的原料。蒸馏过程也依赖于精确的温度、压力和其他因素来确保纯度。 大麻植物本身富含四氢大麻酚和生物多样性,但也有数百种其他潜在的有价值的大麻素。例如,CBN,CBG,CBC和THCV是罕见的大麻素,仅占植物总质量的0.01%至10%。生产相对少量的稀有大麻素需要大量的植物质量。 稀有大麻素-来源:稀有大麻素公司 对于寻求用于大规模生产的特定稀有大麻素的制药公司来说,这些动态尤其成问题。合成大麻素提供了一个引人注目的替代品,但这些分子缺乏萜烯的随从效应。新的研究表明,萜类化合物可能对某些临床结果产生积极影响。 生物收获科学公司(CSE:BHSC)从一株含有所需活性植物大麻素的单一母株开始。然后,科学家们从植物中取出小部分,在含有营养物质的固体培养基上培养培养皿中的细胞。这些细胞成为自然界的一个缩影,在它们的原始结构中含有来自母株的成分。 这些细胞现在构成了一个“细胞库”,用于永久和同质的生产。然后,它们可以在大型生物反应器中的液体培养基中生长,周期为3-4周,相当于每年13-17个周期。此外,生物包装过程在无菌条件下进行,完全符合ISO和GMP的要求,消除了污染的可能性。 在细胞达到足够的生物量后,它们被干燥成最终的粉末形式。该粉末含有所需的活性植物大麻素和其他植物特性,创造一个随从效果。这些粉末是理想的使用大麻素为基础的食品,饮料,或药品需要完美的指纹一致性。 生物装备的好处-来源:生物收获 除了无与伦比的一致性和快速的生产周期之外,生物修复过程使用的水、能源和其他资源比传统种植少得多。鉴于美国西部缺水,在室内种植大麻需要大量能源,这些属性至关重要。 生物收获科学公司(CSE:BHSC)已经建立了一个令人印象深刻的生物包装平台,能够扩大有价值的大麻素的生产。 该公司已经利用该平台从红葡萄中大规模提取有价值的植物化学物质。它的Vinia®产品线是一个专有的红葡萄产品,含有整个基质的多酚在红葡萄。每份400毫克的葡萄酒所含的皮赛德白藜芦醇量相当于一整瓶葡萄酒。 同样的平台可能会彻底改变大麻行业,因为该公司还将目光投向通过其他产品释放橄榄和石榴的好处。 欲了解更多信息,请访问公司网站或下载他们的投资者演示文稿。 免责声明 以上文章为赞助内容。cannabisfn.com和CFN Media被雇来提高认识。请按以下链接查看我们概述赔偿的完整披露: 本文由CFN Enterprises Inc.(OTCQB:CNFN)发表,该公司是CFN Media的所有者和运营商,CFN Media是行业领先的机构和数字金融媒体网络,致力于新兴的CBD和合法大麻行业。请致电+1(833)420-CNFN了解更多信息。